Education
About Us
Working with TipRanks
Follow Us
Concord Biotech Ltd. (IN:CONCORDBIO)
:CONCORDBIO
RESEARCH TOOLSreports
Total Valuation
Concord Biotech Ltd. has a market cap or net worth of ₹189.78B. The enterprise value is ₹155.63B.
Market Cap₹189.78B
Enterprise Value₹155.63B
Share Statistics
Concord Biotech Ltd. has 104,616,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding104,616,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Concord Biotech Ltd.’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 18.35%.
Return on Equity (ROE)0.21
Return on Assets (ROA)0.18
Return on Invested Capital (ROIC)18.35%
Return on Capital Employed (ROCE)0.24
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.59
Inventory Turnover2.55
Valuation Ratios
The current PE Ratio of Concord Biotech Ltd. is 0.00. Concord Biotech Ltd.’s PEG ratio is 1.78.
PE Ratio0.00
PS Ratio0.00
PB Ratio10.20
Price to Fair Value0.00
Price to FCF86.60
Price to Operating Cash Flow58.65
PEG Ratio1.78
Income Statement
In the last 12 months, Concord Biotech Ltd. had revenue of 12.00B and earned 3.72B in profits. Earnings per share was 35.52.
Revenue12.00B
Gross Profit5.89B
Operating Income4.52B
Pretax Income4.96B
Net Income3.72B
EBITDA5.51B
Earnings Per Share (EPS)35.52
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Concord Biotech Ltd. pays an annual dividend of ₹8.75, resulting in a dividend yield of 0.48%
Dividend Per Share₹8.75
Dividend Yield0.48%
Payout Ratio24.56%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.82
52-Week Price Change16.12%
50-Day Moving Average1.71K
200-Day Moving Average1.90K
Relative Strength Index (RSI)45.96
Average Volume (3m)10.80K
Important Dates
Concord Biotech Ltd. upcoming earnings date is Sep 3, 2025, Before Open (Confirmed).
Last Earnings DateMay 29, 2025
Next Earnings DateSep 3, 2025
Ex-Dividend DateJun 21, 2024
Financial Position
Concord Biotech Ltd. as a current ratio of 6.17, with Debt / Equity ratio of 0.64%
Current Ratio6.17
Quick Ratio4.87
Debt to Market Cap0.00
Net Debt to EBITDA<0.01
Interest Coverage Ratio853.88
Taxes
In the past 12 months, Concord Biotech Ltd. has paid 1.23B in taxes.
Income Tax1.23B
Effective Tax Rate0.25
Enterprise Valuation
Concord Biotech Ltd. EV to EBITDA ratio is <0.01, with an EV/FCF ratio of 0.01.
EV to Sales<0.01
EV to EBITDA<0.01
EV to Free Cash Flow0.01
EV to Operating Cash Flow<0.01
Balance Sheet
Concord Biotech Ltd. has ₹2.84B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹2.84B billion.
Cash & Marketable Securities₹2.84B
Total Debt₹0.00
Net Cash-₹2.84B
Net Cash Per Share-₹27.12
Tangible Book Value Per Share₹0.00
Margins
Gross margin is 75.47%, with operating margin of 37.66%, and net profit margin of 30.97%.
Gross Margin75.47%
Operating Margin37.66%
Pretax Margin41.32%
Net Profit Margin30.97%
EBITDA Margin45.89%
EBIT Margin41.36%
Analyst Forecast
The average price target for Concord Biotech Ltd. is ₹1,850.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target₹1,850.00
Price Target Upside10.98% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―